Related Experiment Video
Updated: Nov 14, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
41.1K
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
Jean Bourbeau1, Mona Bafadhel2, Neil C Barnes3,4
1Respiratory Epidemiology and Clinical Research Unit, Department of Medicine, McGill University and Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Summary
Single-inhaler triple therapy (SITT) significantly reduces exacerbations and hospitalizations in COPD patients, with benefits outweighing pneumonia risks. Personalized treatment decisions are crucial for optimal patient outcomes.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Trials
Background:
- Chronic obstructive pulmonary disease (COPD) presents significant healthcare and socioeconomic challenges.
- Personalized treatment strategies are recommended to manage COPD symptoms and reduce exacerbations.
- Single-inhaler triple therapy (SITT) combining LAMA, LABA, and ICS is being investigated for symptomatic COPD.
Purpose of the Study:
- To review evidence on the benefits and risks of SITT in COPD patients.
- To evaluate SITT's impact on lung function, patient-reported outcomes, and exacerbations.
- To discuss the role of blood eosinophils in predicting ICS response and guiding treatment decisions.
Main Methods:
- Review of randomized controlled trials (RCTs) investigating SITT.
- Comparison of SITT with dual therapies (LAMA/LABA).
- Analysis of benefits (lung function, exacerbations, mortality) versus risks (pneumonia).
Main Results:
- SITT demonstrates benefits in lung function and patient-reported outcomes compared to dual therapies.
- Significant reductions in exacerbations and hospitalizations are observed with SITT.
- While ICS use is associated with increased pneumonia risk, SITT's benefits are considered to outweigh this risk.
Conclusions:
- SITT offers significant advantages in managing symptomatic COPD, particularly in reducing exacerbations and hospitalizations.
- Blood eosinophil counts can aid in predicting ICS response and informing personalized treatment strategies.
- Treatment decisions for COPD should balance benefit versus risk, emphasizing early optimization for long-term patient outcomes.
Related Concept Videos
01:23Inhaled Medications
532
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
532
01:26COPD: Management Using Bronchodilators and Corticosteroids
539
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
539
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:30Asthma-IV: Diagnostic and Management
2.8K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.8K
01:22Chronic Obstructive Pulmonary Disease
1.8K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.8K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.4K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.4K